Phase 3 Data Published in Lancet Show bendamustine (LevactÂ®) Plus Rituximab Doubles Progression-Free Survival in Patients With Indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma Compared With CHOP-R